PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats

Zhenming Yu1,*, Yongqing Zhu1,*, Alice S. Chen-Plotkin4,*, Dana Clay-Falcone5, Leo McCluskey4, Lauren Elman4, Robert G. Kalb4,7, John Q. Trojanowski5,6, Virginia M.-Y. Lee5,6, Viiviana M. Van Deerlin5,6, Aaron D. Gitler3,*, Nancy M. Bonini1,2,6

1 Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 2 Howard Hughes Medical Institute, Philadelphia, Pennsylvania, United States of America, 3 Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 4 Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 5 Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 6 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 7 Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating, rapidly progressive disease leading to paralysis and death. Recently, intermediate length polyglutamine (polyQ) repeats of 27–33 in ATAXIN-2 (ATXN2), encoding the ATXN2 protein, were found to increase risk for ALS. In ATXN2, polyQ expansions of ≥34, which are pure CAG repeat expansions, cause spinocerebellar ataxia type 2. However, similar length expansions that are interrupted with other codons, can present atypically with parkinsonism, suggesting that configuration of the repeat sequence plays an important role in disease manifestation in ATXN2 polyQ expansion diseases. Here we determined whether the expansions in ATXN2 associated with ALS were pure or interrupted CAG repeats, and defined single nucleotide polymorphisms (SNPs) rs695871 and rs695872 in exon 1 of the gene, to assess haplotype association. We found that the expanded repeat alleles of 40 ALS patients and 9 long-repeat length controls were all interrupted, bearing 1–3 CAA codons within the CAG repeat. 21/21 expanded ALS chromosomes with 3CAA interruptions arose from one haplotype (GT), while 18/19 expanded ALS chromosomes with <3 CAA interruptions arose from a different haplotype (CC). Moreover, age of disease onset was significantly earlier in patients bearing 3 interruptions vs fewer, and was distinct between haplotypes. These results indicate that CAG repeat expansions in ATXN2 associated with ALS are uniformly interrupted repeats and that the nature of the repeat sequence and haplotype, as well as length of polyQ repeat, may play a role in the neurological effect conferred by expansions in ATXN2.

Introduction

Amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig’s disease) is a progressive, fatal neurodegenerative disease caused by the degeneration of motor neurons [1–3]. Approximately 10% of ALS cases are familial, with the remainder of cases being sporadic. To date, 12 genetic loci have been identified associated with familial ALS. Among these, mutations in superoxide dismutase 1 (SOD1) account for 15–20% of cases of familial ALS [4]. Trans-activate repress DNA-binding protein (TARDBP, or TDP-43) is a major disease protein of the ubiquitin-positive cytoplasmic inclusions in ALS without SOD1 mutations [5]. Mutations in the TDP-43 coding gene TARDBP were later found in multiple cases of familial and sporadic ALS [6–9], indicating that TDP-43 plays a critical role in disease pathogenesis.

Spinocerebellar ataxia 2 (SCA2) is an autosomal dominant disease caused by an expanded CAG trinucleotide repeat encoding glutamine within the open reading frame of the gene encoding the ataxin 2 protein, ATAXIN2 (ATXN2) [10–12]. As with other polyglutamine (polyQ) diseases, the length of the CAG repeat expansion is inversely correlated with disease onset and severity [13]. CAG repeats in normal alleles of ATXN2 are variable in length, although by far the most common allele carries 22 repeats. In the normal ATXN2 allele, the CAG repeat region encoding the glutamine domain is typically interrupted by one or more CAA repeats (also encoding glutamine). The CAG repeat region within expanded alleles of ATXN2 associated with SCA2 disease are 34–59 in length [10–12,14–19]. Similar to other polyQ diseases, SCA2 is for the most part a “pure” repeat disease. That is, the
expanded allele is comprised of an uninterrupted sequence of CAGs encoding glutamine. However, four years after the 1996 identification of expansions in ATXN2 as the molecular basis of SCA2, a pathogenic length expansion bearing an “interrupted” repeat sequence was first reported [20]. It is now recognized that lower-range polyQ repeat expansions in ATXN2, of 33–49 in length, can be associated with levodopa responsive parkinsonism [21–30]. Intriguingly, in the situations of parkinsonism sequenced to date, the CAG repeat region has been found to not be a pure CAG repeat run, but rather to be interrupted with one or more CAA (or other) codons [21–30].

Additional data suggests that two SNPs (rs695871 and rs695872) in exon 1 of the ATXN2 gene, where the CAG repeat region occurs, predominant in distinct patterns in normal versus SCA2 individuals: the GT haplotype predominates in controls, whereas the CC haplotype is associated with disease [19].

Recently, intermediate-length polyQ repeats in ATXN2 were found to be a significant risk factor for ALS [31]. Consistent with the association between ATXN2 and ALS, it was previously known that SCA2 can present with motor neuron features that mimic ALS [32,33]. Thus, it appears that individuals with repeat expansions in ATXN2 can present with SCA2, parkinsonism, or ALS depending upon the length of the repeat. Moreover, the finding that ATXN2-linked parkinsonism may be associated with an interrupted CAG repeat region, versus the pure CAG repeats typical of SCA2, raises the possibility that the CAG purity of the repeat expansion may contribute to disease manifestation.

Given these data, we sequenced the polyQ repeat region within ATXN2 in the cases of ALS and controls harboring ATXN2 polyQ repeats of 27 and higher [31]. Our results show that the repeats associated with increased risk for ALS are uniformly comprised of interrupted CAG repeats. All of the sequences are interrupted by 1–3 CAA codons; none of the repeats harbors a pure CAG repeat. Further, SNP analysis using the derived cleaved amplified polymorphic sequences (dCAPS) technique [34] revealed that the alleles with 3 CAA codons are the GT haplotype, whereas alleles with fewer CAA codons are predominantly the CC haplotype. Age of disease onset in subjects with ALS and 3 CAA repeat interruptions, compared to those with fewer, revealed that the age of onset was significantly earlier; age of disease onset also differed by haplotype. This is despite the fact that the average repeat length is shorter in subjects with 3 CAA interruptions. These results highlight that an interplay of the CAG repeat sequence configuration, haplotype association, as well as repeat length, may play a prominent role in disease manifestation in ATXN2-associated neuropathologies.

**Results**

**CAA interruptions in the CAG repeat region of ATXN2 in ALS**

We characterized the repeat sequence in 40 of the 45 ALS cases with intermediate length polyQ repeats in the ATXN2 gene of 27–33 in length and nine of the control cases [31]; these constituted a subset of 40 ALS cases we previously reported with expanded ATXN2 alleles for which motor neuron disease was the initial presentation and from which we were able to obtain amplifiable DNA. All 40 cases met El Escorial criteria for ALS; in addition, for 19/40 cases (those from the University of Pennsylvania Center for Neurodegenerative Disease Research (CNDR)) clinical charts were available and reviewed by a neurologist to confirm the diagnosis of ALS. With the exception of one previously described individual with ataxic features late in the course of disease (case A14, Table 1; [31]), these 19 well-characterized cases did not demonstrate features atypical of ALS such as parkinsonism or ataxia.

The ATXN2 repeat region was amplified by polymerase chain reaction from genomic DNA samples. Because the repeats were intermediate in length compared to the normal allele (22 or 23), it was difficult to cleanly separate the allele bearing the longer repeat from the normal allele. Thus, we were unable to sequence the DNA directly from the PCR product and determine the sequence with high integrity. Instead, the amplification products were separated by size on a 4% agarose gel, then extracted, and expanded alleles subcloned and sequenced. Multiple clones for each allele were sequenced to assure against PCR-introduced changes.

The length of the normal allele of the ALS patients was typically 22; this is consistent with previous findings that a repeat of 22 is the most common normal allele [16,17,19,35]. For the longer alleles, in ALS patients (n = 40 with ATXN2 expansion), the repeats ranged from 27 to 33, and in controls (n = 9 with ATXN2 expansions) from 27 to 32. Sequencing of the repeat region revealed that none of the polyQ repeats in patients with ALS were comprised of pure CAG repeat expansions. Rather, all were interrupted by at least 1 CAA codon, in stark contrast to the situation observed in SCA2. Interruptions of the repeat sequence are typical of the intermediate expansion repeats observed in control individuals [19]. Note that such interruptions do not affect the protein sequence, as CAA also encodes glutamine. Analysis of the repeat length patterns indicated that the repeat region was interrupted by 1, 2 or 3 CAA codons. Aside from the striking finding that none of the repeats were pure CAG repeats, we also observed among the Q27 repeats a monomorphic sequence pattern of 3 CAA interruptions in an 8-4-4-8 configuration.

In order to determine whether or not the polyQ repeat sequence was distinct among patients with repeat lengths within the ALS-susceptibility range and controls, we also sequenced 9 neurologically normal individuals with repeat lengths of 27 and longer (Table 2). This analysis confirmed that the polyQ-encoding DNA sequence was also interrupted in controls, and, moreover, bore interruption patterns found among the ALS patients. Thus, the controls of 27 had the same repeat configuration as the ALS patients; there was also no distinguishing feature among the controls with repeat lengths of 29, 30 and 32—these DNAs showed interrupted repeat patterns also found among ALS patients. Taken together, these data indicate that intermediate-length polyQ repeats in the ATXN2 gene associated with ALS are CAA interrupted repeats bearing interruptions of 1, 2 or 3 CAA codons.

**Association of the haplotype of rs695871 and rs695872 with CAA interruptions in ATXN2**

Two SNPs are found in exon 1 which bears the polyQ domain of ATXN2. rs695871 is 177 bp upstream of the repeat, and bears either a G or C base; the polymorphism affects the amino acid sequence, changing a Val to a Leu. The second SNP rs695872 is a T or C, and is silent, with no effect on the protein sequence. Others have previously reported that these two SNPs define two distinct haplotypes, a CC haplotype that appears to be evolutionarily ancestral and a GT haplotype of more recent origin; the CC haplotype predominates among SCA2 expanded alleles [19,36]. Using dCAPS, to introduce a restriction enzyme site depending upon the polymorphism to allow the SNPs to be defined by polymerase chain amplification followed by restriction enzyme analysis [34], we defined these polymorphisms in the ALS
patients and control cases (Figure 1; Tables 1 and 2). This analysis showed that the 1 and 2 CAA interruption situations were predominantly associated with the CC haplotype (18/19 expanded chromosomes), whereas the 3 CAA interrupted alleles were uniformly the GT haplotype (21/21 chromosomes). This distinction was also the case for the intermediate length alleles among the controls.

Association of the number of CAA interruptions and haplotype in ATXN2 with age of disease onset among the ALS patients

We considered whether the number of CAA interruptions within the repeat region and/or the genetic background in the form of SNP haplotype might result in differences in disease...
Table 2. Sequence of the polyQ repeat region of expanded alleles of controls.

| Case ID | Atx2 length | Age at sampling | CAG Pattern | SNP expanded allele | CAA # | Pattern |
|---------|-------------|-----------------|-------------|--------------------|-------|---------|
| N11     | 27          | 80              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N12     | 27          | 65              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N13     | 27          | 62              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N14     | 27          | 61              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N15     | 27          | 74              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N16     | 27          | 73              | 8-4-4-8     | GT                 | 3     | OOOOOOOO
| N22     | 29          | 59              | 8-4-4-10    | GT                 | 3     | OOOOOOOO
| N23     | 30          | 57              | 21-8        | CC                 | 1     | OOOOOOOO
| N24     | 32          | 59              | 13-8-9      | CC                 | 2     | OOOOOOOO

**SNP695871 SNP695872.**
doi:10.1371/journal.pone.0017951.t002

Discussion

Multiple faces of ATXN2 in neurological disease

PolyQ expansions in ATXN2 are now associated with three clinically distinct neurological diseases; these different situations are associated with different repeat lengths and sequence configuration of the DNA repeat region (Figure 3). If the polyQ domain within ATXN2 is composed of a pure CAG repeat with a length ≥34, this presents with SCA2 [10–12,14–19]. However, repeat expansions in ATXN2 can also present with levo-dopa responsive parkinsonism; about half of these situations have been sequenced. The repeat lengths range from 33 to 49, and in the situations sequenced, the polyQ domain is not a pure CAG repeat run, but rather comprised of an interrupted CAG repeat region [22–30]. Further, recent studies indicate that intermediate-length polyQ repeats in ATXN2 of 27 to 33 are associated with increased risk for ALS [31], although the precise repeat length cut-off is likely to vary depending upon the population [38]. Here we show that ALS-associated polyQ repeats in ATXN2 are uniformly interrupted CAG repeats, comprised of interruptions of 1–3 CAA codons. We also observed a haplotype distinction between individuals bearing 3CAA interruptions and fewer. Note that CAA also encodes glutamine, thus the repeat region within the protein will remain a pure polyQ domain. These data suggest that the length of the polyQ repeat, as well as the CAG-repeat purity of the repeat region and the haplotype, influence disease presentation.

RNA toxicity in ATXN2-related neuropathology

That interrupted and uninterrupted polyQ repeat expansions with similar length in ATXN2 lead to different neurological presentations (SCA2 or parkinsonism) highlights the possibility that repeat sequence configuration, as well as repeat length, is an important arbiter in clinical manifestation and phenotypic variability in ATXN2-associated pathologies. SCA2 is known to show nigral atrophy and motor neuron loss; that is, the clinical manifestations of parkinsonism and motor neuron disease are within the spectrum of SCA2 pathology [39–41]. Intriguingly, select situations appear biased strongly toward one neurological outcome or another; interestingly, this may be influenced by not only the length of the repeat, but also the purity of the CAG repeat region encoding the polyQ expansion.
PolyQ disease is classically viewed as a purely protein-based disease, with dominant toxicity conferred by the expanded polyQ domain [13,37]. However, some data suggest that the situation may be more complicated, and that pathogenic mechanisms beyond toxicity or abnormal interactions solely due to the polyQ-containing protein may contribute to polyQ expansion diseases. For example, toxicity at the level of the expanded repeat RNA is conferred by CAG expansions in *Drosophila* [42], *C elegans* and mammals [43,44].

Notably, CAA interruptions within the repeat sequence for SCA3 shift the toxicity curve, such that expression of a polyQ protein of identical amino acid sequence, but encoded by a CAA/G interrupted repeat region, is less toxic [42]. In the context of human disease, interruptions may present with different manifestations, or different clinical features of disease being dominant. In potential support of this idea, interruption of the CAG repeat polymorphism by an AT in a TBP repeat region was reported to cause later onset and milder disease in a rare case of SCA1 compared to pure, uninterrupted repeats of similar length [45]. An intriguing situation also occurs in SCA17, which is due to polyQ repeat expansions in TATA-box binding protein (TBP) [46-48]. Normally, the polyQ repeat region within TBP is interrupted by multiple CAA codons, and remains so in the expanded disease situation. Intriguingly, the threshold for a pathogenic repeat length is higher for repeat expansions for SCA17 (~44) compared to that of most of the dominantly inherited spinocerebellar ataxias (~37) [13,49]. It is tempting to speculate that this shifted toxicity curve for SCA17 may be due to the interrupted repeat sequence of the polyQ domain within TBP.

Our findings are consistent with the idea that both the presence of any CAA interruptions and the presence of increasing numbers of CAA interruptions may influence phenotypic presentation. Specifically, while the overwhelming majority of SCA patients have pure CAG repeat expansions [10–12,37,41], 40/40 ALS patients in this study had at least one CAA interruption. Among these 40 patients with CAA interruptions, the number of interruptions as well as the haplotype may matter. Here we found an earlier age at onset for those ALS patients with more interruptions and who also share the GT haplotype.

The 3CAA-interrupted chromosomes arose on one genetic background (the GT haplotype), and most <3CAA-interrupted chromosomes arose on a different genetic background (the CC haplotype). We found both an association between earlier age at onset and number of CAA interruptions as well as SNP haplotype. Moreover, the fact that the ALS patients are not associated with a single haplotype may explain why ATXN2 has not emerged as a significant contributor to ALS from genome wide association (GWA) studies [50–53]. Intriguingly, however, a SNP linked to a gene that interacts with ATXN2, Ataxin-2 binding protein, has been identified as significant [50,54]. Our previous study found an earlier age of disease onset in a small cohort of ALS patients (n = 65), when comparing those bearing a longer ATXN2 repeat to those with a normal length repeat [31]; it is possible that those data were driven by patients with 3CAA interruptions in the repeat sequence, of the GT haplotype. As with all such findings, such trends require confirmation among larger and additional sets of patients.

How might the sequence within the repeat region influence disease presentation? Whether the repeat sequence is a pure CAG or an interrupted CAG is predicted to influence somatic instability of the repeat, with a pure repeat being far more unstable and tending to expand [19,55–57]. CAA interruptions have been
proposed to play a critical role in conferring stability to the CAG repeat in ATXN2, with their absence predisposing ATXN2 alleles towards instability and pathogenic expansion to SCA2 disease [19]. Interruptions in a CAG repeat RNA by CAA codons are predicted to affect the secondary structure [50]. Even the interruption of a single CAA codon can have a notable effect on structure and free energy of folding. Moreover, if, as with other expanded repeat RNAs such as CGG expanded RNA of FXS/TAS [59,60] and expanded CAG repeats of myotonic dystrophy [61], the CAG repeat RNA interacts with select proteins, the altered structure due to CAA interruptions may result in differential interactions. Such differential protein or other interactions may in part contribute to the distinct disease manifestations. The purity of the repeat may also influence the level of the mRNA and/or level of the translated protein. Such an influence of the RNA may be notable for ALS, as defects in RNA processing and metabolism may particularly relevant. The association of mutations in TDP43 and expanded repeat RNAs such as CGG expanded RNA of FXTAS and SCA2-B (5'-CGGGCTTGCGGACATTGG-3') mismatch underlined) was used such that one mismatch was introduced to generate a recognition site for the restriction endonuclease AvaII (recognition site 5'-AATG/TAATG-3'). Products covering the SNP and polyQ repeat region were amplified with primers SCA2-AVAII and SCA2-B (5'-CGGGCTTGCGGACATTGG-3') using LA tag DNA polymerase as above. Undigested and AvaII-digested products were separated on a 4% agarose gel in parallel. AvaII could only cut the amplified product if the SNP were a C and not a G. Thus, the SNP (C or G) and linkage to the normal or expanded allele were determined by the digestion pattern. For SNP695871, Primer SCA2-NOTI (5'-ccttcctccgctccaggggctccctccggggccacccggtg CCTCCCCGCTGGCCGCGC-3', mismatch underlined) was used such that one mismatch was introduced to generate a recognition site for the restriction endonuclease NotI (recognition site 5'-GCC-GGGGC-3'). Products spanning the SNP and polyQ region were amplified with primers SCA2-NOTI and SCA2-B. Undigested and NotI-digested products were separated on a 4% agarose gel in parallel. NotI could only cut the amplified product if the SNP were a C and not T. Thus, the SNP (C or T) and the linkage to the normal or expanded allele were determined by the digestion pattern.

Statistics

Survival curve analyses using log-rank tests were used to compare age at onset, disease duration, gender, and presence/absence of atypical features between subgroups of ALS patients with 1, 2 and 3CAA interruptions, and between subgroups of ALS patients with different genetic backgrounds.

Acknowledgments

We are truly grateful for the dedication of the patients and their families and for their invaluable contributions to this research.

Author Contributions

Conceived and designed the experiments: ZY YZ ASC-P ADG. Performed the experiments: YZ ASC-P ADG. Analyzed the data: ZY YZ ASC-P ADG NMB. Contributed reagents/materials/analysis tools: DG-F LM LE RGK JQT VM-YL VMV. Wrote the paper: ZY YZ ASC-P ADG NMB.

References

1. Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806–819.
2. Chen-Pokhans AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6: 211–220.
3. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7: 710–723.
4. Rosen DR, Siddique T, Patterson D, Fidowicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62.
5. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133.
6. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, et al. (2008) TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 63: 535–538.
7. Kahashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572–574.
8. Kuhlenkamp P, Sperfeld AD, Vannmessen B, Van Deerlin V, Lee VM, et al. (2008) Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol 65: 1105–1109.
9. Stroehlhanz J, Blau J, Tripathi VB, Hu X, Vance C, et al. (2008) TDP-43 expression in hippocampal neurons in vivo. Nat Neurosci 11: 1668–1672.
10. Wolod SP, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14: 269–276.
11. Sanpei K, Takano H, Igarashi S, Sato T, Oya N, et al. (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14: 277–284.
12. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, et al. (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14: 283–291.

13. Guseela JF, MacDonald ME (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109–115.

14. Canel G, Duur A, Didierjean O, Imbert G, Burk K, et al. (1997) Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet 6: 709–715.

15. Geschwind DH, Perlman S, Figueroa CP, Treiman LJ, Puls ST (1997) The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 60: 842–850.

16. Lorenzozzi D, Bohlega S, Zoghbi HY (1997) The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. Neurology 49: 1009–1013.

17. Ginioli F, Sabadini G, Sweeney MG, Davis MB, Vezzani A, et al. (1998) The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlations. Brain 121(Pt 5): 459–467.

18. Saleem Q, Cho-Sorisky M, Sankar B, Pai DMV, Vidyasagar S, et al. (2000) Molecular analysis of autosomal dominant hereditary ataxias in the Indian population: high frequency of SCA2 and evidence for a common founder mutation. Hum Genet 106: 179–187.

19. Choudhrty S, Mekari S, Nevastava AK, Jain S, Brahmacabhi SK (2001) CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. Hum Mol Genet 10: 2437–2446.

20. Costanzo-Porrini S, Tassarollo D, Abbressoci C, Liguori M, Ashizawa T, et al. (2000) An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 54: 491–493.

21. Kim JM, Song S, Kim GP, Choi YJ, Kim YK, et al. (2007) Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 64: 1510–1514.

22. Gwinn-Hardy K, Chen JY, Liu HC, Liu TY, Boss M, et al. (2000) Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 55: 800–805.

23. Shan DE, Song BW, Sun CM, Lee SJ, Liao KK, et al. (2001) Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 50: 812–815.

24. Furtado S, Farrer M, Tsuboi Y, Klimek ML, de la Fuente-Fernandez R, et al. (2002) SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology 59: 1625–1627.

25. Lu CS, Wu Chou YH, Kuo PC, Chang HC, Weng YH (2004) The parkinsonian neuron disease. Mov Disord 19: 848–852.

26. Costanzo-Porrini S, Tassarollo D, Abbressoci C, Liguori M, Ashizawa T, et al. (2000) An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 54: 491–493.

27. Kim JM, Song S, Kim GP, Choi YJ, Kim YK, et al. (2007) Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 64: 1510–1514.

28. Gwinn-Hardy K, Chen JY, Liu HC, Liu TY, Boss M, et al. (2000) Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 55: 800–805.

29. Shan DE, Song BW, Sun CM, Lee SJ, Liao KK, et al. (2001) Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 50: 812–815.

30. Modoni A, Contarino MF, Bentivoglio AR, Tabolacci E, Santoro M, et al. (2004) The parkinsonian syndrome of SCA-2: genetic, cellular and PET findings. Neurology 59: 1625–1627.

31. Costanzo-Porrini S, Tassarollo D, Abbressoci C, Liguori M, Ashizawa T, et al. (2000) An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 54: 491–493.

32. Kim JM, Song S, Kim GP, Choi YJ, Kim YK, et al. (2007) Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 64: 1510–1514.

33. Gwinn-Hardy K, Chen JY, Liu HC, Liu TY, Boss M, et al. (2000) Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 55: 800–805.

34. Shan DE, Song BW, Sun CM, Lee SJ, Liao KK, et al. (2001) Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 50: 812–815.

35. Modoni A, Contarino MF, Bentivoglio AR, Tabolacci E, Santoro M, et al. (2004) Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinson's disease patients. Mov Disord 22: 324–327.

36. Socci MP, Emmel VE, Kiedler CR, Hillig A, Saraiva-Pereira ML, et al. (2009) Intrahemispheric variability of Parkinson phenotype in SCA6: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat Disord 15: 374–378.

37. Wada H, Xia H, Xia X, Guo LF, Jin P, et al. (2009) Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: genetic, clinical, and postmortem emmission tomography findings. Mov Disord 24: 2007–2011.

38. Elden A, Kim HJ, Hart M, Chen-Plotkin A, Johnson B, et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased susceptibility to amyotrophic lateral sclerosis. Nature 466: 1069–1075.

39. Infante J, Berciano J, Volpini V, Corral J, Polo JM, et al. (2004) Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord 19: 848–852.

40. Nanni T, Fancellu R, Tomasello C, Geller C, Parpesy D, et al. (2009) Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol 256: 1926–1928.

41. Neff MM, Nolf JD, Goody J, Pepper AE (1998) CACPs, a simple technique for the genetic analysis of single nucleotide polymorphisms: experimental applications in Arabidopsis thaliana genetics. Plant J 14: 387–392.

42. Kieß O, Laccoane FA, Gisert S, Schols I, Zuhlike C, et al. (1997) SCA2 trinucleotide expansion in German SCA2 patients. Neurogenetics 1: 59–64.

43. Ramos EM, Martins S, Alonso I, Emmel VE, Saraiva-Pereira ML, et al. (2009) Common origin of pure and interrupted repeat expansions in spinocerebellar ataxia type 2 (SCA2). Am J Med Genet B Neuropsychiatr Genet 153B: 324–331.